 | Up a level |
Journal Article
Herbst, Sophie A., Vesterlund, Mattias 
ORCID: 0000-0001-9471-6592, Helmboldt, Alexander J. ORCID: 0000-0002-0807-7518, Jafari, Rozbeh ORCID: 0000-0002-3396-4709, Siavelis, Ioannis, Stahl, Matthias, Schitter, Eva C., Liebers, Nora, Brinkmann, Berit J., Czernilofsky, Felix, Roider, Tobias, Bruch, Peter-Martin, Iskar, Murat ORCID: 0000-0001-8603-4313, Kittai, Adam, Huang, Ying, Lu, Junyan ORCID: 0000-0002-9211-0746, Richter, Sarah, Mermelekas, Georgios, Umer, Husen Muhammad, Knoll, Mareike, Kolb, Carolin, Lenze, Angela, Cao, Xiaofang, Osterholm, Cecilia, Wahnschaffe, Linus, Herling, Carmen, Scheinost, Sebastian, Ganzinger, Matthias, Mansouri, Larry, Kriegsmann, Katharina, Kriegsmann, Mark, Anders, Simon ORCID: 0000-0003-4868-1805, Zapatka, Marc, Del Poeta, Giovanni, Zucchetto, Antonella, Bomben, Riccardo, Gattei, Valter, Dreger, Peter, Woyach, Jennifer, Herling, Marco, Muller-Tidow, Carsten, Rosenquist, Richard ORCID: 0000-0002-0211-8788, Stilgenbauer, Stephan, Zenz, Thorsten, Huber, Wolfgang, Tausch, Eugen, Lehtioe, Janne and Dietrich, Sascha
(2022).
Proteogenomics refines the molecular classification of chronic lymphocytic leukemia.
Nat. Commun., 13 (1).
BERLIN:
NATURE PORTFOLIO.
ISSN 2041-1723
Liebers, Nora, Duell, Johannes, Fitzgerald, Donnacha ORCID: 0000-0003-4927-7484, Kerkhoff, Andrea, Noerenberg, Daniel, Kaebisch, Eva ORCID: 0000-0001-7752-4126, Acker, Fabian ORCID: 0000-0002-6207-0237, Fuhrmann, Stephan ORCID: 0000-0002-7785-2565, Leng, Corinna, Welslau, Manfred, Chemnitz, Jens, Middeke, Jan-Moritz, Weber, Thomas, Holtick, Udo, Trappe, Ralf, Pfannes, Roald, Liersch, Ruediger, Spoer, Christian, Fuxius, Stefan, Gebauer, Niklas, Caille, Leandra, Geer, Thomas, Koenecke, Christian, Keller, Ulrich, Claus, Rainer, Mougiakakos, Dimitrios, Mayer, Stephanie, Huettmann, Andreas, Pott, Christiane, Trummer, Arne, Wulf, Gerald, Brunnberg, Uta, Bullinger, Lars ORCID: 0000-0002-5890-5510, Hess, Georg, Mueller-Tidow, Carsten, Glass, Bertram, Lenz, Georg, Dreger, Peter and Dietrich, Sascha
(2021).
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Blood Adv., 5 (13).
S. 2707 - 2717.
AMSTERDAM:
ELSEVIER.
ISSN 2473-9537